Background The purpose of this study was to investigate the outcomes of gefitinib and
erlotinib in patients with non-small cell lung cancer (NSCLC) with uncommon epidermal …

Background: A phase III trial was conducted to compare the safety and efficacy of erlotinib
with that of gefitinib in advanced non-small cell lung cancer harbouring epidermal growth …

Introduction: Somatic mutations in the epidermal growth factor receptor gene (EGFR) are
associated with a marked therapeutic response to EGFR–tyrosine kinase inhibitors (TKIs) in …

BACKGROUND: This study prospectively assessed the efficacy of gefitinib and the survival
benefit for non-small cell lung cancer (NSCLC) patients with epidermal growth factor …

Purpose The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …

Backgrounds Efficacy of gefitinib therapy strongly depends on epidermal growth factor
receptor (EGFR)-mutation status in Asian patients with non-small cell lung cancer. Recently …

Purpose: Most lung cancers with activating epidermal growth factor receptor (EGFR)
mutations respond to gefitinib; however, resistance to this tyrosine kinase inhibitor (TKI) …

Key “driver” mutations have been discovered in specific subgroups of non-small-cell lung
cancer (NSCLC) patients. Activating mutations in the form of deletions in exon 19 (del 19) or …

Objective Somatic mutations in the epidermal growth factor receptor gene are associated
with a therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors …

Introduction: In non–small-cell lung cancer, an exon 19 deletion and an L858R point
mutation in the epidermal growth factor receptor (EGFR) are predictors of a response to …